Patents by Inventor David A. Engers
David A. Engers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11299458Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.Type: GrantFiled: August 14, 2020Date of Patent: April 12, 2022Assignee: OTSUKA AMERICA PHARMACEUTICAL, INC.Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
-
Patent number: 10800740Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.Type: GrantFiled: March 11, 2019Date of Patent: October 13, 2020Assignee: OTSUKA AMERICA PHARMACEUTICAL, INC.Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
-
Publication number: 20200039934Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.Type: ApplicationFiled: March 11, 2019Publication date: February 6, 2020Inventors: Anthony Alexander MCKINNEY, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
-
Patent number: 10280141Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.Type: GrantFiled: November 21, 2017Date of Patent: May 7, 2019Assignee: OTSUKA AMERICA PHARMACEUTICAL, INC.Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
-
Publication number: 20180194726Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.Type: ApplicationFiled: November 21, 2017Publication date: July 12, 2018Inventors: Anthony Alexander MCKINNEY, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
-
Patent number: 9856217Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.Type: GrantFiled: June 1, 2017Date of Patent: January 2, 2018Assignee: NEUROVANCE, INC.Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
-
Patent number: 9708261Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.Type: GrantFiled: June 17, 2016Date of Patent: July 18, 2017Assignee: NEUROVANCE, INC.Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
-
Publication number: 20160136148Abstract: The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a-vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60° C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient.Type: ApplicationFiled: November 10, 2015Publication date: May 19, 2016Applicant: NOVEN THERAPEUTICS, LLCInventors: David A. Engers, Yonglai Yang, Stephen Parent, Travis Houston, Bruce Charles Friedman
-
Patent number: 9211290Abstract: The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a -vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60° C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient.Type: GrantFiled: March 15, 2013Date of Patent: December 15, 2015Assignee: NOVEN THERAPEUTICS, LLCInventors: David A. Engers, Yonglai Yang, Stephan Parent, Travis Houston, Bruce Charles Friedman
-
Publication number: 20130158264Abstract: Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, pharmaceutical compositions, and uses thereof. The invention includes methods of treating diseases such as cancer, including cancer mediated at least in part by IGF-1 R and/or IR, with the polymorphs and compositions. This Abstract is not limiting of the invention.Type: ApplicationFiled: June 23, 2011Publication date: June 20, 2013Inventors: Arlindo L. Castelhano, David A. Enger, Jason A. Hanko, Josef A. Rechka, Jing Teng, Yonglai Yang
-
Patent number: 6221400Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors are described.Type: GrantFiled: January 6, 1999Date of Patent: April 24, 2001Assignee: Elan Pharma International LimitedInventors: Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu
-
Patent number: 6068858Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increased rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HV-2) protease inhibitors are described.Type: GrantFiled: January 6, 1999Date of Patent: May 30, 2000Assignee: Elan Pharma International LimitedInventors: Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu
-
Patent number: 6045829Abstract: The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increase rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors are described.Type: GrantFiled: July 9, 1997Date of Patent: April 4, 2000Assignee: Elan Pharma International LimitedInventors: Gary G. Liversidge, David A. Engers, Mary E. Roberts, Stephen B. Ruddy, Sui-Ming Wong, Shuqian Xu
-
Patent number: 5571536Abstract: Nanoparticulate crystalline drug substances formulated in an aqueos phase emulsified in oil, are able to be made at less than 1000 nm size and provide increased bioavailability and lymphatic uptake following oral administration.Type: GrantFiled: February 6, 1995Date of Patent: November 5, 1996Assignee: Nano Systems L.L.C.Inventors: W. Mark Eickhoff, Karl R. Mueller, David A. Engers
-
Patent number: 5560931Abstract: Nanoparticulate crystalline drug substances formulated in an aqueos phase emulsified in oil, are able to be made at less than 1000 nm size and provide increased bioavailability and lymphatic uptake following oral administration.Type: GrantFiled: February 14, 1995Date of Patent: October 1, 1996Assignee: NawoSystems L.L.C.Inventors: W. Mark Eickhoff, Karl R. Mueller, David A. Engers
-
Patent number: 5518738Abstract: A composition comprising a crystalline NSAID having polyvinylpyrrolidone adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm, hygroscopic sugar and sodium lauryl sulfate exhibit greatly reduced gastric irritation following oral administration and/or hastened onset of action due to the substantial redispersion of the solid formulation to nanoparticles in gastric fluid.Type: GrantFiled: February 9, 1995Date of Patent: May 21, 1996Assignee: NanoSystem L.L.C.Inventors: W. Mark Eickhoff, David A. Engers, Karl R. Mueller